Since its establishment in 2005, the HonorHealth Research Institute has achieved many accomplishments. They include:
- More than 5,000 patients receiving expanded care through clinical trials.
- More than 200 investigators developing and conducting research in the HonorHealth system.
- Completing more than 500 clinical trials.
- Impacting the value of science and medicine through hundreds of publications.
Accomplishments by year:
- Established as an institute with a $4.5 million Piper Trust grant to develop biosciences and establish personalized medicine in oncology at Scottsdale Healthcare.
- Launched a relationship with University of Arizona Cancer Center to bring oncology clinical trials and expertise to Scottsdale.
- Named Daniel Von Hoff, MD, as chief scientific officer.
- Established a partnership with the Translational Genomics Research Institute (TGen).
- Accepted a $5 million donation from the Stardust Foundation.
- Established Phase I oncology clinical trial program infrastructure.
- Began Phase I study of gemcitabine combined with abraxane clinical trial for treatment of pancreatic cancer.
- Began the Bisgrove Trial, the first one developed in collaboration with TGen to investigate and prove the use of molecular profiling to target tumors and select therapies.
- Began Phase I Hedgehog Pathway clinical trial for the treatment of metastatic solid tumors, successfully treating the first person in the world.
- Launched the Drug Development Scholar Program to develop the next generation of clinical investigators.
- Completed construction of the building and opened the Bisgrove Research Pavilion.
- Established research as a requirement to the first American College of Surgeons Level 1 trauma designation at Scottsdale Healthcare Osborn Medical Center.
- Received an $18 million Stand Up to Cancer Award for the Pancreatic Cancer Dream Team. The institute was the first site to complete and publish positive results from the trial, a collaboration between Johns Hopkins, the Salk Institute, Columbia University and University of Pennsylvania.
- Began the Bariatric Research Program with two clinical trials for specialized devices for obesity.
- Obtained FDA approval for the use of Xience V Everolimu Eluting Coronary Stent System for coronary disease.
- Obtained FDA approval for the use of rivaroxaban for stroke prevention in patients with afibrillation.
- Received the second-fastest FDA drug approval in history for the Hedgehog Pathway-Erivedge for metastatic basal cell cancer.
- Received FDA approval for the drug combination of Gemcitabine and Abraxane trial, which became the standard for using drug combinations for cancer treatments.
- Launched RADAR (rapid detection and assessment of response), a program using new imaging technologies to look at patients’ responses to targeted therapy. Established with a $100,000 grant from the Scottsdale Industrial Development Authority.
- Awarded a $200,000 grant from the Flinn Foundation to investigate the relationship of the microbiome and ventilator-associated pneumonia.
- FDA approval of the Maestro system for vagal nerve block and weight management.
- FDA approval for the Reshape double gastric balloon, a nonsurgical device for treatment of obesity.
- The institute was renamed the HonorHealth Research Institute.
- Scottsdale runner received the first fully dissolving heart stent approved by FDA after clinical trials performed at the institute.
- Stand Up 2 Cancer grant award.